NCT05962606 2026-03-18
Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.
Aptarion Biotech AG
Phase 2 Completed
Aptarion Biotech AG
Creative Biosciences (Guangzhou) Co., Ltd.
BioAegis Therapeutics Inc.
Carebot s.r.o.
MedImmune LLC